Stock EDIT EDITAS MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Real-time Estimate Cboe BZX
Other stock markets
 16:55:12 26/06/2024 BST 		5-day change 1st Jan Change
4.865 USD -2.11% Intraday chart for Editas Medicine, Inc. -4.27% -52.37%
06-14 Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial MT
06-14 Editas Medicine, Inc. Reports New Safety and Efficacy Data from the Rubber Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association Annual Congress CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Editas Medicine Reports New Safety And Efficacy Data From The RUBY Trial Of Reni-Cel In 18 Patients With Sickle Cell Disease, Presented At The European Hematology Association Annual Congress
AQ
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
MT
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
GL
Editas Medicine, Inc. Reports New Safety and Efficacy Data from the Rubber Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association Annual Congress
CI
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
GL
Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association Annual Congress
CI
Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating
MT
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
MT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
GL
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
AQ
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting
AQ
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
GL
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating
MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight
MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024
Editas: Q1 Earnings Snapshot
AQ
Editas Medicine Announces First Quarter 2024 Results and Business Updates
GL
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
GL
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EDIT Stock
  4. News Editas Medicine, Inc.